ImmunityBio Stock Forecast

Stock Price Forecast

According to 3 analysts polled by S&P Global, ImmunityBio stock has a consensus rating of "Strong Buy" and an average price target of $13. The average 1-year stock price forecast is 66.67% higher than the current stock price, while the lowest is $12 (+53.85%) and the highest is $15 (+92.31%).

Price Target: $13 (+66.67%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$12	$13	$12	$15
Change	+53.85%	+66.67%	+53.85%	+92.31%

Analyst Ratings

The average analyst rating for ImmunityBio stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	4	3	4	3	2	2
Buy	1	1	1	1	1	1
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	5	4	5	4	3	3

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Andres Y. Maldonado H.C. Wainwright	H.C. Wainwright	Buy Reiterates $15	Buy	Reiterates	$15	+92.31%	Jun 2, 2026
Edward Tenthoff Piper Sandler	Piper Sandler	Buy Reiterates $12	Buy	Reiterates	$12	+53.85%	Jun 1, 2026
Jeet Mukherjee BTIG	BTIG	Buy Maintains $13 → $12	Buy	Maintains	$13 → $12	+53.85%	May 8, 2026

Financial Forecast

Revenue This Year

222.38M

from 113.29M

96.30%

from 113.29M

Revenue Next Year

452.02M

from 222.38M

103.26%

from 222.38M

EPS This Year

-0.79

from -0.38

EPS Next Year

0.06

from -0.79

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	934.00K	240.00K	622.00K	14.75M	113.29M	222.38M
Revenue Growth	54.38%	-74.30%	159.17%	2,270.58%	668.32%	96.30%
Gross Profit	934.00K	240.00K	622.00K	14.75M	112.54M	218.60M
Gross Margin	100.00%	100.00%	100.00%	100.00%	99.34%	98.30%
Operating Income	-317.42M	-350.67M	-361.36M	-344.18M	-256.03M	-249.60M
Net Income	-346.79M	-416.57M	-583.20M	-413.56M	-351.40M	-880.78M
EPS	-	-	-	-	-0.38	-0.79
Free Cash Flow	-170.30M	-299.03M	-234.66M	-256.31M	-213.36M	-526.32M
No. Analysts	-	-	-	-	-	3

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	251.8M
Avg	222.4M
Low	198.2M

Revenue Growth

Revenue Growth	2026	2027	2028
High	122.3%
Avg	96.3%
Low	75.0%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-0.79
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-